Vivus shares buoyed as FDA allows early resubmission on Qnexa

Will the second time prove the charm for Vivus? Some investors were betting that way this morning, driving up the biotech's share value by 14% on the news that it had come to terms with the FDA on an early resubmission of the obesity drug Qnexa. Last fall, of course, Vivus ($VVUS) shares were blighted by the FDA's rejection of Qnexa based on regulators fear of the cardio risks presented by the...